As the role of immunotherapies extends to earlier treatment lines in the nonmelanoma skin cancer treatment armamentarium, increased attention to patient characteristics and disease factors is crucial to ensure all patients receive tolerable therapies at the optimal time during the course of their disease, according to Vishal Patel, MD, FAAD, FACMS.
Read the OncLive® article.
